Plasticell is developing therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology.
It is advancing a number of therapeutic programs, including the expansion of hematopoietic stem cells from bone marrow and cord blood, the manufacture of red blood cells, platelets and immune cells from induced pluripotent stem cells (iPSCs).
Plasticell collaborates with leading universities and industry partners to facilitate discovery and improve product manufacturing in a variety of high value areas such as cell therapy, gene therapy, cancer immunotherapy and drug discovery.
Plasticell and GSK have studied the role of drugs on platelet formation and also the regeneration of human tissues as part of a collaboration with its sister company Progenitor Therapeutics.
We have been awarded Biomedical Catalyst funding to perform a project aimed at concluding pre-clinical development of an ex vivo expanded stem cell product derived from cord blood, in collaboration with Anthony Nolan and the Francis Crick Institute... plasticell.co.uk/articles/press…